| Applicability of 2022 classifications of acute myeloid leukemia in the real-world setting E Attardi, A Savi, B Borsellino, A Piciocchi, M Cipriani, T Ottone, E Fabiani, ... Blood Advances 7 (17), 5122-5131, 2023 | 3 | 2023 |
| HEALTH-RELATED QUALITY OF LIFE OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA AFTER DISCONTINUATION OF TYROSINE KINASE INHIBITORS: RESULTS FROM THE EURO-SKI STUDY F Efficace, FXFX Mahon, J Richter, A Piciocchi, M Cipriani, FE Nicolini, ... HemaSphere 7 (S3), 2023 | 3 | 2023 |
| The Addition of Venetoclax to Induction Chemotherapy in No Low-Risk AML Patients: A Propensity Score-Matched Analysis of the Gimema AML1718 and AML1310 Trials A Piciocchi, M Messina, M Cipriani, F Paoloni, G Simonetti, R Palmieri, ... Blood 140 (Supplement 1), 137-138, 2022 | 2 | 2022 |
| A randomized double-blind clinical trial on safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis … FL Lombardo, S Spila Alegiani, F Mayer, M Cipriani, M Lo Giudice, ... Trials 24 (1), 792, 2023 | 1 | 2023 |
| P523: THE COMPARISON OF VFLAI, FLAI AND 3+ 7 REGIMENS BY MULTILEVEL PROPENSITY SCORE WEIGHTING HIGHLIGHTS THE BENEFIT OF THE ADDITION OF VENETOCLAX IN NO LOW-RISK AML TREATED … A Piciocchi, G Marconi, M Cipriani, M Messina, F Guolo, P Minetto, ... HemaSphere 7 (S3), e0034216, 2023 | 1 | 2023 |
| Addition of venetoclax to FLAI induction chemotherapy (VFLAI) improves survival in patients with intermediate and high-risk AML vs FLAI and 3+ 7: A GIMEMA Italian cooperative … G Martinelli, M Cipriani, G Marconi, F Guolo, P Minetto, F Paoloni, ... Journal of Clinical Oncology 41 (16_suppl), 7013-7013, 2023 | 1 | 2023 |
| Unlocking the potential of synthetic patients for accelerating clinical trials: Results of the first GIMEMA experience on acute myeloid leukemia patients A Piciocchi, M Cipriani, M Messina, G Marconi, V Arena, S Soddu, E Crea, ... Ejhaem 5 (2), 353-359, 2024 | | 2024 |
| A Propensity Score Weighting Analysis Emphasizes the Progress of the Gimema Approach in Adult Ph-Positive Acute Lymphoblastic Leukemia in the TKI Era A Piciocchi, S Chiaretti, M Cipriani, M Messina, L Elia, I Della Starza, ... Blood 142, 4200, 2023 | | 2023 |
| Unraveling the Impact of 2022 Classifications on Secondary Acute Myeloid Leukemia: Assessing the True Qualification Power of Diagnostic Qualifiers E Attardi, A Savi, B Borsellino, M Cipriani, A Piciocchi, F Mallegni, ... Blood 142, 819, 2023 | | 2023 |
| The Promotoer, a brain-computer interface-assisted intervention to promote upper limb functional motor recovery after stroke: a statistical analysis plan for a randomized … M Cipriani, F Pichiorri, E Colamarino, J Toppi, F Tamburella, M Lorusso, ... Trials 24 (1), 736, 2023 | | 2023 |
| P499: APPLICABILITY OF 2022 CLASSIFICATIONS OF ACUTE MYELOID LEUKEMIA IN THE REAL-WORLD SETTING E Attardi, A Savi, B Borsellino, A Piciocchi, M Cipriani, T Ottone, E Fabiani, ... HemaSphere 7 (S3), e5402602, 2023 | | 2023 |
| P495: UNLOCKING THE POTENTIAL OF SYNTHETIC PATIENTS FOR ACCELERATING CLINICAL TRIALS: RESULTS OF THE FIRST GIMEMA EXPERIENCE A Piciocchi, M Cipriani, M Messina, G Marconi, V Arena, S Soddu, E Crea, ... HemaSphere 7 (S3), e4536536, 2023 | | 2023 |
| S159: HEALTH-RELATED QUALITY OF LIFE OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA AFTER DISCONTINUATION OF TYROSINE KINASE INHIBITORS: RESULTS FROM THE EURO-SKI STUDY F Efficace, FX Mahon, J Richter, A Piciocchi, M Cipriani, FE Nicolini, ... HemaSphere 7, e0972454, 2023 | | 2023 |
| Pseudo-observations in survival analysis M Cipriani, A Piciocchi, V Arena, M Alfò SIS 2023 - Statistical Learning, Sustainability and Impact Evaluation, 590, 2023 | | 2023 |
| Health-Related Quality of Life and Financial Burden of Ethiopian Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitors F Tadesse, A Gebremedhin, A Abubeker, A Piciocchi, M Cipriani, ... Blood 140 (Supplement 1), 5264-5265, 2022 | | 2022 |
Alfonso PiciocchiGIMEMA Foundation, RomeVerified email at gimema.it
